Qi Li1,2, Andrew D Warren1, Adnan I Qureshi3, Andrea Morotti4, Guido J Falcone5, Kevin N Sheth5, Ashkan Shoamanesh6, Dar Dowlatshahi7, Anand Viswanathan1, Joshua N Goldstein8. 1. Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. 2. Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. 3. Zeenat Qureshi Stroke Institute, St. Cloud, MN, USA. 4. Department of Neurology and Neurorehabilitation, IRCCS Mondino Foundation, Pavia, Italy. 5. Department of Neurology, Yale School of Medicine, New Haven, CT, USA. 6. Division of Neurology, McMaster University/Population Health Research Institute, Hamilton, Ontario, Canada. 7. Department of Medicine (Neurology), Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada. 8. Division of Neurocritical Care and Emergency Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Abstract
OBJECTIVE: The aim was to investigate whether intensive blood pressure treatment is associated with less hematoma growth and better outcome in intracerebral hemorrhage (ICH) patients who received intravenous nicardipine treatment ≤2 hours after onset of symptoms. METHODS: A post-hoc exploratory analysis of the Antihypertensive Treatment of Acute Cerebral Hemorrhage 2 (ATACH-2) trial was performed. This was a multicenter, international, open-label, randomized clinical trial, in which patients with primary ICH were allocated to intensive versus standard blood pressure treatment with nicardipine ≤4.5 hours after onset of symptoms. We have included 913 patients with complete imaging and follow-up data in the present analysis. RESULTS: Among the 913 included patients, 354 (38.7%) had intravenous nicardipine treatment initiated within 2 hours. In this subgroup of patients treated within 2 hours, the frequency of ICH expansion was significantly lower in the intensive blood pressure reduction group compared with the standard treatment group (p = 0.02). Multivariable analysis showed that ultra-early intensive blood pressure treatment was associated with a decreased risk of hematoma growth (odds ratio, 0.56; 95% confidence interval [CI], 0.34-0.92; p = 0.02), higher rate of functional independence (odds ratio, 2.17; 95% CI, 1.28-3.68; p = 0.004), and good outcome (odds ratio, 1.68; 95% CI, 1.01-2.83; p = 0.048) at 90 days. Ultra-early intensive blood pressure reduction was associated with a favorable shift in modified Rankin Scale score distribution at 3 months (p = 0.04). INTERPRETATION: In a subgroup of ICH patients with elevated blood pressure given intravenous nicardipine ≤2 hours after onset of symptoms, intensive blood pressure reduction was associated with reduced hematoma growth and improved functional outcome. ANN NEUROL 2020;88:388-395.
OBJECTIVE: The aim was to investigate whether intensive blood pressure treatment is associated with less hematoma growth and better outcome in intracerebral hemorrhage (ICH) patients who received intravenous nicardipine treatment ≤2 hours after onset of symptoms. METHODS: A post-hoc exploratory analysis of the Antihypertensive Treatment of Acute Cerebral Hemorrhage 2 (ATACH-2) trial was performed. This was a multicenter, international, open-label, randomized clinical trial, in which patients with primary ICH were allocated to intensive versus standard blood pressure treatment with nicardipine ≤4.5 hours after onset of symptoms. We have included 913 patients with complete imaging and follow-up data in the present analysis. RESULTS: Among the 913 included patients, 354 (38.7%) had intravenous nicardipine treatment initiated within 2 hours. In this subgroup of patients treated within 2 hours, the frequency of ICH expansion was significantly lower in the intensive blood pressure reduction group compared with the standard treatment group (p = 0.02). Multivariable analysis showed that ultra-early intensive blood pressure treatment was associated with a decreased risk of hematoma growth (odds ratio, 0.56; 95% confidence interval [CI], 0.34-0.92; p = 0.02), higher rate of functional independence (odds ratio, 2.17; 95% CI, 1.28-3.68; p = 0.004), and good outcome (odds ratio, 1.68; 95% CI, 1.01-2.83; p = 0.048) at 90 days. Ultra-early intensive blood pressure reduction was associated with a favorable shift in modified Rankin Scale score distribution at 3 months (p = 0.04). INTERPRETATION: In a subgroup of ICH patients with elevated blood pressure given intravenous nicardipine ≤2 hours after onset of symptoms, intensive blood pressure reduction was associated with reduced hematoma growth and improved functional outcome. ANN NEUROL 2020;88:388-395.
Authors: Andrea Morotti; H Bart Brouwers; Javier M Romero; Michael J Jessel; Anastasia Vashkevich; Kristin Schwab; Mohammad Rauf Afzal; Christy Cassarly; Steven M Greenberg; Renee Hebert Martin; Adnan I Qureshi; Jonathan Rosand; Joshua N Goldstein Journal: JAMA Neurol Date: 2017-08-01 Impact factor: 18.302
Authors: J N Goldstein; L E Fazen; R Snider; K Schwab; S M Greenberg; E E Smith; M H Lev; J Rosand Journal: Neurology Date: 2007-03-20 Impact factor: 9.910
Authors: Craig S Anderson; Emma Heeley; Yining Huang; Jiguang Wang; Christian Stapf; Candice Delcourt; Richard Lindley; Thompson Robinson; Pablo Lavados; Bruce Neal; Jun Hata; Hisatomi Arima; Mark Parsons; Yuechun Li; Jinchao Wang; Stephane Heritier; Qiang Li; Mark Woodward; R John Simes; Stephen M Davis; John Chalmers Journal: N Engl J Med Date: 2013-05-29 Impact factor: 91.245
Authors: Craig S Anderson; Yining Huang; Hisatomi Arima; Emma Heeley; Christian Skulina; Mark W Parsons; Bin Peng; Qiang Li; Steve Su; Qing Ling Tao; Yue Chun Li; Jian Dong Jiang; Li Wen Tai; Jin Li Zhang; En Xu; Yan Cheng; Lewis B Morgenstern; John Chalmers; Ji Guang Wang Journal: Stroke Date: 2009-12-31 Impact factor: 7.914
Authors: Stephan A Mayer; Stephen M Davis; Brett E Skolnick; Nikolai C Brun; Kamilla Begtrup; Joseph P Broderick; Michael N Diringer; Thorsten Steiner Journal: Stroke Date: 2009-01-15 Impact factor: 7.914
Authors: Craig S Anderson; Yining Huang; Ji Guang Wang; Hisatomi Arima; Bruce Neal; Bin Peng; Emma Heeley; Christian Skulina; Mark W Parsons; Jong Sung Kim; Qing Ling Tao; Yue Chun Li; Jian Dong Jiang; Li Wen Tai; Jin Li Zhang; En Xu; Yan Cheng; Stephane Heritier; Lewis B Morgenstern; John Chalmers Journal: Lancet Neurol Date: 2008-04-07 Impact factor: 44.182
Authors: Matthew B Maas; Alexander J Nemeth; Neil F Rosenberg; Adam R Kosteva; Shyam Prabhakaran; Andrew M Naidech Journal: Neurology Date: 2013-03-20 Impact factor: 9.910
Authors: Joseph P Broderick; James C Grotta; Andrew M Naidech; Thorsten Steiner; Nikola Sprigg; Kazunori Toyoda; Dar Dowlatshahi; Andrew M Demchuk; Magdy Selim; J Mocco; Stephan Mayer Journal: Stroke Date: 2021-04-08 Impact factor: 7.914
Authors: Andrea Morotti; Gregoire Boulouis; Andreas Charidimou; Qi Li; Loris Poli; Paolo Costa; Valeria De Giuli; Eleonora Leuci; Federico Mazzacane; Giorgio Busto; Francesco Arba; Laura Brancaleoni; Sebastiano Giacomozzi; Luigi Simonetti; Michele Laudisi; Giuseppe Micieli; Anna Cavallini; Elisa Candeloro; Massimo Gamba; Mauro Magoni; Andrew D Warren; Christopher D Anderson; M Edip Gurol; Alessandro Biffi; Anand Viswanathan; Ilaria Casetta; Enrico Fainardi; Andrea Zini; Alessandro Pezzini; Alessandro Padovani; Steven M Greenberg; Jonathan Rosand; Joshua N Goldstein Journal: Neurology Date: 2021-04-01 Impact factor: 9.910